Substituted Indole Compounds for TLR7/8/9 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent and stable compounds that can act as antagonists for Toll-like receptors 7, 8, and 9 to address aberrant activation leading to autoimmune diseases and inflammatory conditions by modulating the immune response.
Innovation Solution
Development of novel substituted indole compounds that can inhibit Toll-like receptor 7, 8, and/or 9 activity, offering a therapeutic approach for autoimmune diseases and inflammatory conditions by administering these compounds or their pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TLR antagonists are used, then TLR activity is inhibited, but the compounds lack stability and effective pharmacokinetic profiles
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of indole compounds through various substitutions at specific positions (R1, R2, X1, X2, X3, Y groups). These structural parameter changes optimize both the TLR inhibition efficacy and the compound stability, while improving pharmacokinetic properties such as metabolic stability and bioavailability.
Solution Approach 2:
The invention creates composite molecular structures by combining the indole core with diverse heterocyclic groups, aromatic rings, and substituent patterns. This composite approach generates compounds with enhanced stability profiles and improved pharmacokinetic characteristics while maintaining potent TLR antagonistic activity.
2Productivity
If TLR7/8/9 activation is enhanced to boost immune response, then adaptive immunity is primed, but aberrant activation leads to autoimmune diseases and chronic inflammation
Solution Approach 1:
The patent applies preliminary anti-action by developing TLR antagonists that prevent aberrant activation before it can lead to autoimmune disease progression. These compounds selectively block overactivated TLRs while preserving normal immune function, thereby preventing the harmful effects of chronic inflammation and autoantibody production without completely suppressing the immune system.
Solution Approach 2:
The invention employs partial action by using TLR antagonists that selectively modulate specific TLR pathways (TLR7, TLR8, TLR9) that are aberrantly activated in autoimmune conditions, while allowing other immune pathways to function normally. This selective inhibition achieves therapeutic benefit without excessive suppression of the overall immune response.
Data Source
AI summary
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.